

FACSIMILE

Date: April 5, 2001	From: Harry B. Shubin
To: Examiner F. Higel U.S. PATENT AND TRADEMARK OFFICE Group Art Unit 1626	MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd., Suite 1400 Arlington, VA 22201 (U.S.A.) (Fax: 703-243-6410)
Faxsimile No.: (703) 308-7921	Writer's Direct Dial: (703) 812-5306
Telephone No.:	Writer's Internet Address: shubinh@uvzb.com
RE: U.S. Patent Application Serial No. 09/755,060 Attorney Docket No.. BAYER-1 D1	
Total No. of Pages: 18; if you do not receive all pages, please call 703-243-6333.	

Dear Examiner Higel:

Attached is a copy of the Preliminary Amendment submitted in the above-referenced application on January 8, 2001. This copy is being provided at your request.

Very truly yours,


Nancy J. Robins
Secretary to Harry B. Shubin

HBS:njr
Attachment

K:\PAT\Bayer\1 D1\fax to Examiner 04.05.01.wpd

Information contained in this facsimile communication may contain privileged and confidential information and is intended solely for the use of the addressee listed above. If you are neither the intended recipient nor the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any disclosure, copying or distribution of, or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone on (703) 243-6333 to arrange for return of the original document to us at our cost. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Jill E. WOOD et al.

Serial No., Div. of 09/083,399

Filed: December 14, 2000

Box: PATENT APPLICATION

Group Art Unit: 1626

Examiner: F. Higel

For:

RAF KINASE INHIBITORS

Please add to file
Patent 07/01/01

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows prior to calculation of the fees.

In the Claims:

Cancel claims 1 to 18 without prejudice or disclaimer.

Amend the claims as follows:

us 1,125
 -19. A method for the treatment of cancerous cell growth mediated by raf kinase,
 comprising administering a compound of the formulae:

